Literature DB >> 21647131

Drug companies hope to breathe life into asthma pipeline.

Mike May.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21647131     DOI： 10.1038/nm0611-642b

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  The tumor necrosis factor family member LIGHT is a target for asthmatic airway remodeling.

Authors:  Taylor A Doherty; Pejman Soroosh; Naseem Khorram; Satoshi Fukuyama; Peter Rosenthal; Jae Youn Cho; Paula S Norris; Heonsik Choi; Stefanie Scheu; Klaus Pfeffer; Bruce L Zuraw; Carl F Ware; David H Broide; Michael Croft
Journal:  Nat Med       Date:  2011-04-17       Impact factor: 53.440

2.  Leukotriene antagonists as first-line or add-on asthma-controller therapy.

Authors:  David Price; Stanley D Musgrave; Lee Shepstone; Elizabeth V Hillyer; Erika J Sims; Richard F T Gilbert; Elizabeth F Juniper; Jon G Ayres; Linda Kemp; Annie Blyth; Edward C F Wilson; Stephanie Wolfe; Daryl Freeman; H Miranda Mugford; Jamie Murdoch; Ian Harvey
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245
  2 in total
  1 in total

Review 1.  Thiol redox chemistry: role of protein cysteine oxidation and altered redox homeostasis in allergic inflammation and asthma.

Authors:  Sidra Hoffman; James Nolin; David McMillan; Emiel Wouters; Yvonne Janssen-Heininger; Niki Reynaert
Journal:  J Cell Biochem       Date:  2015-06       Impact factor: 4.429
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.